Varian Pharmed

What Varian Pharmed does

Varian Pharmed is an Iranian knowledge-based pharmaceutical company specializing in extended-release injectable drug delivery. Founded in 2009-2010 and headquartered in Tehran, it operates as a subsidiary of Golrang Pharmaceutical Group and employs 51-100 staff, including an R&D team of more than 40 PhD and master's-level specialists across pharmacy, engineering, and chemistry. Its commercial portfolio spans more than 20 products across six therapeutic areas: endocrinology, gynecology and IVF, oncology, anesthesia and analgesia, addiction treatment, and general medications. Customer-facing brands include Leupromer (leuprorelin acetate), Variopeptyl (triptorelin acetate), Variotide LAR (octreotide), CetroArt (cetrorelix), Variorelix (ganirelix), sustained-release Buprenorphine, Marcovar (bupivacaine), and Vario-Mitexan (mesna).

The company's two proprietary technology platforms — In-Situ Forming Implants (ISFI) and Microspheres — underpin its differentiation. ISFI formulations are liquid systems that transform into gel-like depots upon contact with body fluids via a solvent exchange mechanism, enabling sustained drug release from one week to several months. Microspheres encapsulate active pharmaceutical ingredients in spherical particles (0.1 to 100 micrometers) for diffusion- or degradation-controlled release. These platforms are supported by eight documented scientific publications/patent records on PLGA-based controlled-release formulations and have produced first-in-Iran products including Sustained-Release Buprenorphine (2025) and Variorelix/Ganirelix (2025). Manufacturing occurs at two GMP-certified sites: a prefilled syringe and ampoule facility in Eshtehard Industrial Park operational since 2021 (1,000+ sqm of clean rooms and a separate 700 sqm QC/QA building), and a biologics-focused site in Kardan acquired in 2024 with capacity to expand.

Varian Pharmed runs a B2B commercial model with direct sales to healthcare providers, hospitals, and clinics, supplemented by a Patient Support Department (established 2019) that has trained 865+ nurses across 655 injection centers in all 31 Iranian provinces. Revenue is generated through one-time pharmaceutical product sales; pricing is not publicly disclosed. The company pursues international expansion through export partnerships and regulatory registrations, with established presence in Syria and Iraq, completed registrations in Kenya and the Philippines, and active filings in Chile, Vietnam, Tunisia, Cameroon, and Thailand. The CEO is Mohammad Taqi Fathi.

Name

Varian Pharmed

Legal name

Varian Pharmed Pharmaceutical Company

Website

https://varianpharmed.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Varian Pharmed is an Iranian pharmaceutical company developing and manufacturing extended-release injectable medications using proprietary In-Situ Forming Implant and Microsphere drug delivery platforms, serving healthcare providers across endocrinology, oncology, gynecology/IVF, anesthesia, and addiction treatment therapeutic areas.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Sterile Injectable Generics (HLAIABAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE)

Keywords

• Extended-release injectables
• Long-acting injectables
• Controlled-release pharmaceuticals
• Drug delivery systems
• Generic injectable medications

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Varian Pharmed generates revenue through the sale of its manufactured pharmaceutical products across multiple therapeutic areas including endocrinology, oncology, gynecology/IVF, anesthesia, and addiction treatment. Products are sold in domestic Iranian market and exported to international markets including Syria and Iraq.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Varian Pharmed develops and manufactures extended-release injectable pharmaceutical products using proprietary In-Situ Forming Implants (ISFI) and Microsphere drug delivery platforms. The company produces over 20 products across six therapeutic areas including endocrinology, oncology, gynecology/IVF, anesthesia and analgesia, addiction treatment, and general medications, supplying hospitals, clinics, and healthcare providers domestically and through export partnerships.

Product overview

Varian Pharmed is a pharmaceutical company specializing in the development and manufacturing of high-quality, extended-release injectable medications. The portfolio is organized across six therapeutic areas: Endocrine (GnRH agonists/antagonists for precocious puberty, prostate cancer, acromegaly), Gynecology and IVF (fertility treatments including GnRH analogs), Oncology (bisphosphonates, uroprotective agents), Anesthesia and Analgesia (local anesthetics, NSAIDs, muscle relaxants), Addiction Treatment (sustained-release buprenorphine), and General (vitamins, antihistamines, H2 antagonists). The core technology platforms are In-situ forming implants and microspheres, enabling extended-release drug delivery. Key products include Leupromer and Variopeptyl (GnRH analogs in multiple strengths), Variotide LAR (somatostatin analog), CetroArt (GnRH antagonist), Buprenorphine ER (ISFI-based sustained-release), and a range of anesthesia/general injectable medications. The company operates two manufacturing sites and distributes products primarily within Iran while pursuing international market expansion.

Differentiator

Problem solved

Functional benefit

Brands

• Leupromer: Brand name for Leuprorelin Acetate products used for central precocious puberty, prostate cancer, and breast cancer treatment
• Variopeptyl
• Variotide LAR
• CetroArt
• Vario-Mitexan
• Zol-Var
• Marcovar
• Variorelix

Products and services

• Leupromer (Leuprorelin Acetate) 3.75, 7.5 mg A GnRH agonist extended-release injectable for the treatment of central precocious puberty, advanced prostate cancer, breast cancer, and endometriosis.
• Variopeptyl (Triptorelin Acetate) 0.1 mg A GnRH agonist injectable solution in prefilled syringe format used as adjunctive therapy in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART).
• Variopeptyl (Triptorelin Acetate) 3.75 mg A GnRH agonist extended-release injectable indicated for central precocious puberty, palliative treatment of advanced prostate cancer, breast cancer, and endometriosis.
• Variopeptyl (Triptorelin Acetate) 11.25 mg A GnRH agonist (triptorelin pamoate) extended-release injectable for central precocious puberty and advanced prostate cancer.
• Variotide LAR (Octreotide Acetate) 20, 30 mg A somatostatin analog extended-release injectable for the treatment of acromegaly, GEP-NET, and other neuroendocrine tumors.
• CetroArt (Cetrorelix) 0.25 mg A GnRH antagonist injectable for the prevention of premature LH surges during controlled ovarian hyperstimulation in IVF/ART treatments.
• Sustained-Release Buprenorphine 100/300 mg A sustained-release buprenorphine product for severe chronic pain management and treatment of opioid dependence, produced using In-situ forming technology, administered subcutaneously once every four weeks.
• Variorelix (Ganirelix) 250 mcg A GnRH antagonist pre-filled syringe for infertility treatment that prevents premature LH surges, delaying premature oocyte maturation.
• Zol-Var (Zoledronic Acid) 4mg/5ml A bisphosphonate injectable for the treatment of hypercalcemia of malignancy, bone metastases, and osteolytic lesions associated with multiple myeloma.
• Vario-Mitexan (Mesna) 400mg/4ml A uroprotective agent used to prevent hemorrhagic cystitis induced by cyclophosphamide and ifosfamide in chemotherapy regimens.
• Ketorolac 15mg/ml and 30mg/ml A nonsteroidal anti-inflammatory drug (NSAID) injectable for the short-term management of moderate to severe acute pain.
• Marcovar (Bupivacaine Hydrochloride) 0.25% A long-acting local anesthetic for use in surgical anesthesia, postoperative pain management, and labor analgesia.
• Methocarbamol 1g/10ml A muscle relaxant injectable used as an adjunct to rest, physical therapy, and other measures for the relief of acute musculoskeletal pain.
• Narpicaine (Ropivacaine) 0.2%, 0.5% A long-acting local anesthetic of the amide type for surgical anesthesia and pain management via epidural, nerve block, or subcutaneous infiltration.
• Pyromol (Acetaminophen) 1g/6.7ml An intravenous analgesic and antipyretic for the management of fever and moderate to severe pain.
• Ondansetron 4mg, 8mg A 5-HT3 receptor antagonist injectable for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiation, and surgery.
• Papaverine Vario 40 mg/mL A vasodilator injectable used for the treatment of vascular spasm, angina pectoris, and erectile dysfunction.
• Biotin Vario 5 mg/mL A vitamin supplement injectable providing biotin for the treatment of biotin deficiency and associated conditions.
• Chlorpheniramine Vario 10 mg/1mL An antihistamine injectable for the treatment of allergic reactions, urticaria, and rhinitis.
• Dexpanthenol Vario 500 mg/2mL A provitamin B5 derivative injectable used for wound healing, skin regeneration, and treatment of postoperative ileus.
• Famotidine 20mg/2ml An H2-receptor antagonist injectable for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and conditions where gastric acid suppression is required.
• VARIO COLD A combination cold medication in oral sachet form for the relief of common cold symptoms including nasal congestion, fever, and pain.

Quantifiable outcome

• Patient Support Department trained over 865 nurses across 655 centers in Iran
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, minor and moderate.

• DelSiTech Ltd.coreTechnology or Integration · 15 February 2025DelSiTech Ltd. supported Varian Pharmed's webinar on Long-Acting Injectable technology, featuring their experts Frederic Douglas, Ph.D., MBA and Lasse Leino. The partnership focuses on knowledge exchange and collaboration in long-acting injectable drug delivery technology.
• University of Southern Denmark (University of Syddansk)minorStrategic or Co-development PartnerProfessor René Holm from the University of Southern Denmark participated as a speaker in Varian Pharmed's webinar on Long-Acting Injectable technology, sharing insights on LAI technology developments.
• TOLMAR PHARMACEUTICALS, INC.minorStrategic or Co-development PartnerDr. Peter Markland from TOLMAR PHARMACEUTICALS participated as a speaker in Varian Pharmed's webinar, contributing expertise on Long-Acting Injectable technology.
• Golrang Pharmaceutical GroupcoreStrategic or Co-development PartnerVarian Pharmed is a subsidiary of Golrang Pharmaceutical Group. Executives from Golrang including CEO Mr. Ashofteh, HR Deputy Dr. Narimani, Strategic Planning Deputy Dr. Mohebi, and Corporate Governance Director Dr. Behrooz visited Varian Pharmed's production facility in Eshtehard Industrial Park for discussions with company management.
• Belarus (Import Partner)moderateChannel Partner/ Reseller/ DistributorBelarusian Ambassador Dmitry Koltsov expressed strong interest in increasing pharmaceutical imports from Iran, particularly advanced medications. The visit was aimed at strengthening trade and diplomatic relations in the healthcare sector and enhancing Iran's pharmaceutical export capacity.
• Switzerland (Raw Material Supplier)moderateOthersSwiss Deputy Ambassador Dr. Julian Briguet and Unicorn CEO Mr. Rezvan visited Varian Pharmed headquarters to discuss collaboration opportunities. Discussions focused on streamlining procurement of high-quality European raw materials. Varian Pharmed emphasizes using high-quality European materials over lower-cost Chinese and Indian sources despite higher prices.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Dr. Reddy's Laboratories: Large diversified generic and specialty injectable manufacturer with a substantial injectable portfolio across endocrinology, oncology, and pain management. Comparable as a broad injectable generic/specialty player with much larger global scale.
• Sun Pharmaceutical Industries: One of the largest generic injectable manufacturers globally with specialty product exposure. Comparable as a broad incumbent in sterile injectable generics with significant emerging-market reach.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a substantial specialty injectable portfolio. Comparable as a broad incumbent across multiple Varian Pharmed therapeutic areas including endocrinology and oncology.
• Hikma Pharmaceuticals: Global specialty pharmaceutical company with a strong injectable generics franchise and MENA regional focus. Comparable on injectable generics breadth and emerging-market distribution model.

Others

• DelSiTech: Finnish drug delivery technology company specializing in long-acting injectable biodegradable silica-based matrices. Directly comparable technology partner and adjacent innovator in LAI drug delivery — the two companies have co-hosted industry webinars together.

Direct peers

• Ferring Pharmaceuticals: Specialty pharma with deep focus on reproductive health and IVF (including GnRH antagonists such as Ganirelix under the brand name). Direct overlap with Varian Pharmed's Variorelix and Variopeptyl product lines in gynecology/ART.
• Tolmar Pharmaceuticals: Specialty pharmaceutical company focused on long-acting injectable (LAI) drug delivery technologies, including polymer-based sustained-release formulations. Directly comparable to Varian Pharmed on platform technology and participated alongside it in industry webinars on LAI development.
• Ipsen: Global specialty pharmaceutical company with a leading franchise in Leuprolide, Triptorelin, and Decapeptyl — exactly the GnRH agonist molecules Varian Pharmed manufactures. Direct competitor in extended-release injectable endocrinology and oncology.

Regional players

• Sobhan Oncology: Iranian specialty pharmaceutical company focused on oncology and supportive care injectables (e.g., bisphosphonates, antiemetics). Comparable as a domestic peer in oncology and hospital injectable segments where Varian Pharmed competes with Zol-Var, Ondansetron, and Mesna.
• Darou Pakhsh Pharma: One of the largest Iranian pharmaceutical manufacturers offering a broad branded generic portfolio across multiple therapeutic areas. Comparable as a domestic Iranian peer competing for the same hospital and institutional formulary positions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/varianpharmed
• Instagraminstagram.com/varian.pharmed

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Varian Pharmed